Loading...
Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20(+) Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma
PURPOSE: The standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL) is salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT). The impact of maintenance rituximab after ASCT is not known. PATIENTS AND METHODS: In total, 477 patients with CD2...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Clinical Oncology
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3646314/ https://ncbi.nlm.nih.gov/pubmed/23091101 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.41.9416 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|